PDCD1 and neoplasm: The use of dual pathway blockade, CTLA‐4 blockade pathway enhancing T cell clones, Treg mediated immunosuppression, and PD‐1 blockade pathway to restore the activity of anticancer cells suggests a significant synergetic effect for an anti‐tumor immune response.